AUTHOR=Mika Thomas , Strate Katharina , Ladigan Swetlana , Aigner Clemens , Schlegel Uwe , Tischoff Iris , Tischer-Zimmermann Sabine , Eiz-Vesper Britta , Maecker-Kolhoff Britta , Schroers Roland 

TITLE=Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes

JOURNAL=Frontiers in Medicine

VOLUME=6

YEAR=2019

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2019.00295

DOI=10.3389/fmed.2019.00295

ISSN=2296-858X

ABSTRACT=<p>Post-transplant lymphoproliferative disease (PTLD) represents a serious complication following allogeneic hematopoietic stem cell transplantation (alloHSCT). Previously, survival rates of PTLD have improved due to the introduction of rituximab. However, reports on curative management of refractory PTLD are scarce. Today, there is no consensus how to treat rituximab-refractory PTLD, especially in highly aggressive disease. Here, we describe successful management of refractory EBV-associated PTLD, specifically DLBCL, with combined brentuximab vedotin and third-party EBV-specific T-cells in a multidisciplinary treatment approach.</p>